Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 18/20 | 0.68 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4010087 | 0.83 | EPHX2 (0.64) | EPHX2EPHX1ALDH1A1 | |
| SCHEMBL4012738 | 0.83 | EPHX2 (0.69) | EPHX2EPHX1ALDH1A1 | |
| SCHEMBL4109537 | 0.81 | EPHX2 (1.00) | EPHX2EPHX1 | |
| SCHEMBL4012121 | 0.79 | EPHX2 (0.63) | EPHX2EPHX1 | |
| SCHEMBL8903167 | 0.75 | NAMPT (0.37) | EPHX2ALDH1A1LMNA | |
| SCHEMBL25934490 | 0.74 | EPHX2 (0.44) | EPHX2EPHX1ALDH1A1 | |
| SCHEMBL3717275 | 0.73 | EPHX2 (0.76) | EPHX2EPHX1 | |
| SCHEMBL4013855 | 0.73 | EPHX1 (0.61) | EPHX2EPHX1ALDH1A1 | |
| SCHEMBL13459453 | 0.71 | CTSK (0.51) | EPHX2EPHX1ALDH1A1 | |
| SCHEMBL2719520 | 0.69 | EPHX2 (1.00) | EPHX2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009086426-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | WO | claimed |
| WO-2009086426-A2 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION | ARETE THERAPEUTICS, INC. (US) | 2009-07-09 | — | — | WO | disclosed |